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Abstract
Background: Adherence to treatment, i.e. the extent to which a patient’s therapeutic engagement coincides with
the prescribed treatment, is among the most important problems in mental health care. The current study
investigated the influence of pairing an acute positive reinforcing dopaminergic/noradrenergic effect
(methylphenidate, MPH) with a standard antidepressant on the rates of adherence to medication treatment. The
primary objective of this study was to determine whether MPH + escitalopram resulted in higher rates of
medication adherence relative to placebo + escitalopram.
Methods: Twenty participants with moderate to severe depression were 1–1 randomized to either (1) 5 mg MPH +
10 mg escitalopram or (2) placebo + 10 mg escitalopram with the possibility for a dose increase at 4 weeks. A
Bayesian analysis was conducted to evaluate the outcomes.
Results: First, neither percent Pill count nor Medication Electronic Monitoring System adherence showed that MPH
was superior to placebo. In fact, placebo showed slightly higher adherence rates on the primary (7.82% better than
MPH) and secondary (7.07% better than MPH) outcomes. There was a less than 25% chance of MPH augmentation
showing at least as good or better adherence than placebo. Second, both groups showed a significant effect of
treatment on the QIDS-SR with a median effect of an 8.6-point score reduction. Third, neither subjective measures
of adherence attitudes nor socio-demographic covariates had a significant influence on the primary or secondary
outcome variables.
Conclusions: These data do not support the use of MPH to increase adherence to antidepressant medication in
individuals with moderate to severe depression.
ClinicalTrials.gov identifier: NCT03388164, registered on 01/02/2018.
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Introduction
Adherence to treatment, i.e. the extent to which the patient’s history of therapeutic engagement coincides with
the prescribed treatment [1], is among the most important problems in mental health care [2, 3]. It is estimated
that nearly half of all prescribed medications are not
taken, that about 125,000 deaths annually are attributable to non-adherence, and that non-adherence costs are
estimated between $100 and $300 billion each year [4].
Thus, non-adherence is a profound clinical challenge
that incurs adverse psychosocial consequences, enormous costs, and poor outcomes that are shared by patients, family members, providers, healthcare systems,
payers, and society [5]. It is estimated that only one out
of five patients comply with antidepressant treatment for
over 4 months [6], and that the majority of patients discontinue antidepressant medication within the first 30
days [7]. Some estimate that the median time to discontinuation of an antidepressant is about two [8] to 4
months [9]. Unfortunately, the majority of clinical trials
do not report rates of adherence and for those that do
only 4 out of 5 participants adhere to the treatment regimen [10], which significantly affects reported efficacy
[11] and safety assessments [12]. There are slight differences between antidepressant medication classes [13],
but low adherence is not limited to medication treatment for depression [14], or even mental health [15, 16].
For example, there is evidence for 25–90% adherence
rates for headache treatments [17]. Moreover, nonadherence extends to other therapeutic modalities, with
about 20 to 70% of individuals who initiate psychosocial
mental health services discontinuing treatment prior to
clinicians’ recommendations [18]. Whereas continued
antidepressant treatment reduces recurrence risk [19],
cardiovascular [20] and overall mortality [21, 22] as well
as suicide rates [23], non-adherence has substantial consequences for the course of depression by increasing relapse [24] or recurrence [25]. Taken together, adherence
to treatment must be considered as one of the most important targets of research seeking to improve therapeutic outcomes.
Building new habits is an important aspect of adherence to any treatment (medication or psychotherapy).
Successfully accomplishing this motivational feat means
that new treatment related behaviors need to change
from a reward-related to a habit-based strategy [26].
New habits can typically be reinforced either by an immediate positive outcome (positive reinforcement), or by
the avoidance of a negative outcome (negative
reinforcement). With respect to depression, there are
several barriers to the formation of new treatment related habits (i.e., adherence behaviors). First, depressed
individuals have reduced hedonic processing mediated
by the dopaminergic system [27], meaning they are less
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driven by what feels “good” or what is “good for the individual”. Therefore, it is often difficult to utilize tools
that may typically act as positive reinforcers in other individuals (e.g. financial payment). Second, habits evolve
from the strong association of a cue (situation or stimulus) with an action [28]. The strengthening of a habit relies primarily on the degree to which a behavior is
expressed “automatically” (without necessary thinking
about it), occurs frequently, and is clearly self-identified.
Successfully cemented habits are highly efficient behaviors, and usually associated with a lack of awareness,
unintentionality, and uncontrollability during their performance. Habit-formation is therefore a complex
process and is likely to take weeks [29]. Prior research
suggests that successful habit-formation likely involves a
transition from reinforcement driven hippocampal circuit activity to stimulus-response driven basal ganglia
driven circuit activity, indicating that it requires a broad
shift in patterns of neural activity [30, 31]. Unfortunately, the functioning of these circuits is preferentially
impaired in depressed individuals [32–35]. It is presently
unclear whether interventions capable of modulating activity in these same neural circuits can improve treatment related habit formation. Third, educational
interventions to enhance adherence have failed to demonstrate a clear benefit on adherence and depression
outcome [36]. Fourth, a community pharmacy-based
coaching program showed no intervention effect on adherence [37]. The premise of this trial was that enhancing dopaminergic activity during the initial phase of
acquiring a new behavior (medication taking) would enhance the transition from action-outcome to habit-based
response selection. Based on these considerations, the
current study aimed to investigate the influence of
pairing a pharmacological agent with an acute positive
reinforcing dopaminergic/noradrenergic effect with a
standard antidepressant on the rates of medication treatment adherence.
Methylphenidate (MPH) has been widely used to treat
attention-deficit/hyperactivity disorder (ADHD) for the
last half century [38]. The drug is a monoaminergic reuptake inhibitor, i.e. it blocks dopamine reuptake transporters [39] and increases dopamine and norepinephrine
availability in the synaptic cleft [40]. MPH has strong affinity at the norepinephrine transporter [41], which exceeds its affinity for the dopamine transporter. However,
its ability to increase NE is much less than that of amphetamine and it has virtually no effect on serotonin
[42]. Moreover, it does not acutely produce a subjective
euphoria, which has been related to its relatively weak
ability to D2 receptors in the striatum [43, 44]. MPH
also has weaker reinforcing properties [45] and has different pharmacokinetic profile [46] than amphetamines
or cocaine, which lowers its relative abuse liability. In
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healthy volunteers, MPH induced improvements in
working memory performance [47], which were associated with reductions in rCBF in the dorsolateral prefrontal cortex and posterior parietal cortex, and reduced
the impact of emotionally arousing material on memory
[48]. Interestingly, MPH has long been considered as a
potential treatment for anxiety based on human and animal studies [49]. For example, MPH has been used for
treating mood, behavior, and cognitive symptoms in individuals with organic brain changes [50] and traumatic
brain injury [51]. In particular, several studies have
shown improvement of cognitive symptoms after treatment with MPH in patients with acute brain injury [52],
including speed of mental processing [53, 54], response
accuracy [55], improved shifts of attention [56], caregiver
ratings of attention [57], and level of depressive symptoms [58]. However, its effects on sustained attention,
distractibility, and memory are less clear [59, 60].
This study aimed to determine whether the combination of a first-line antidepressant plus MPH relative to
a first-line antidepressant plus placebo result in higher
rates of medication adherence in individuals with moderate to severe depression. The primary objective of this
study was to determine whether MPH + escitalopram results in higher rates of medication adherence relative to
placebo + escitalopram. The secondary objective was to
determine whether MPH + escitalopram results in
greater consistency of adherence relative to placebo +
escitalopram.

Materials and methods
Trial description

This Phase 2a randomized placebo-controlled clinical trial
included two principal study arms, with an option to escalate the dose of escitalopram at week 4: (1) Study Drug
A: 5 mg placebo + 10 mg escitalopram (encapsulated into
one capsule) and (2) Study Drug B: 5 mg methylphenidate
(MPH) + 10 mg escitalopram (encapsulated into one capsule). The pilot study was part of a two-stage design which
aimed to enroll 100 subjects with depression who were to
be randomized to one of the two conditions: escitalopram
with placebo (n = 10) or escitalopram with MPH (n = 10)
in Stage 1 and escitalopram with placebo (n = 40) or escitalopram with MPH (n = 40) in Stage 2. Participants randomized to either condition were prescribed medication
over the course of 8 weeks, with in-person follow-up visits
at weeks 0, 2, 4 and 8, with follow-up phone calls on
weeks 1, 3 and 6. Participants randomized to each condition continued to receive usual care as defined by the
treating clinician, with the restriction that participants in
this group were not allowed to receive other new treatments during the study period. The trial was terminated
at the end of Stage 1 due to the results of the pilot study
showing the opposite direction to the hypothesis and low
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posterior probabilities that MPH is superior to the placebo. Therefore, Stage 2 of the study was not completed.
The study was registered with the ClinicalTrials.gov Identifier NCT03388164 on 01/02/2018. The recruitment and
follow-up period were between 01/02/2018 and 05/15/
2018. A CONSORT diagram for the study is shown in
Supplemental Fig. 1.
Endpoints

The primary endpoint for adherence [61] was percent
(%) Pill count as defined by 100 * [number of prescribed
pills – number of pills remaining]/[number of days between dispensing date and return date]. The secondary
endpoint for adherence was defined according to the
STAR-D [62] protocol based on the Medication Electronic Monitoring System (MEMS) (Aardex), i.e. the %
of doses taken on schedule within 25% of the expected
time interval, defined as ±6 h from when the participant
usually took the medication, estimated by fitting a line
to their dosing times. Exploratory endpoints included
the Beliefs About Medicines Questionnaire (BMQ [63])
– accepting/ambivalent vs. indifferent/skeptical, remission as defined by a score of 5 the QIDS-SR, and response as defined by a 50% reduction in symptoms on
the QIDS-SR.
Participants

The participants met the following inclusion criteria for
study eligibility (which was closely matched on STARD): (1) baseline QIDS-SR ≥ 14 (moderate depression
[64]), (2) age 18–65 years, (3) ability to give written informed consent, (4) MDD single-episode/recurrent, not
in remission. Study demographics are described in
Table 1. Individuals with the following exclusion criteria
at baseline were excluded from study participation: (1)
MPH-related exclusions [65] (i.e. uncontrolled hyperthyroidism, glaucoma, motor tics, monoamine oxidase
inhibitor treatment, serious coronary artery disease, cardiomyopathy, serious cardiac arrhythmias, uncontrolled hypertension, peripheral vasculopathy, pregnancy), (2) diagnosis
with the following mental health conditions: bipolar disorder, psychotic disorder, current substance use disorder
(other than nicotine), current alcohol use disorder, (3) history of intolerability of study medications, and (4) currently
taking psychiatric medications.
Study participants were recruited through the clinical
services of the Laureate Psychiatric Clinic and Hospital
(LPCH), local service providers for behavioral health and
mental health, and through online, newspaper, flyer,
radio or other media advertisements in the Tulsa metropolitan area. Participants were also recruited through a
pre-approved Laureate Institute for Brain Research
(LIBR) Screening protocol (WIRB #20101611) and
through existing participants drawn from the LIBR
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Table 1 Demographic Characteristics of the Sample
p

Placebo

MPH

n

10

10

Age (mean (sd))

31.00 (10.58)

31.50 (10.73)

0.918

Sex = Male (%)

2 (20.0)

3 (30.0)

1.000

Height (mean (sd))

65.78 (2.68)

66.50 (4.22)

0.666

Weight (mean (sd))

177.56 (50.33)

180.50 (30.93)

Race (%)
Hispanic/Latino

0 (0.0)

1 (10.0)

Native American

1 (10.0)

2 (20.0)

White

9 (90.0)

7 (70.0)

0 (0.0)

10 (100.0)

Every-Day Smokers

2 (22.2)

0 (0.0)

Former Smokers

2 (22.2)

3 (30.0)

Never Smokers

5 (55.6)

7 (70.0)

Drug = MPH (%)

0.878
0.453

Current Smoker (%)

< 0.001
0.288

Alcohol Use in last 30 days (mean (sd))

3.70 (9.30)

1.70 (2.79)

0.523

BMQ overuse (mean (sd))

12.50 (3.14)

11.80 (2.74)

0.602

BMQ general harm (mean (sd))

15.20 (2.10)

15.50 (2.07)

0.751

QIDS (mean (sd))

17.90 (2.73)

16.67 (2.12)

0.290

REDCap database. Informed consent was obtained by
members of the research team that received training
from the principal investigator to obtain consent for this
study. All participant interactions were conducted in private interview/exam rooms. Data collection occurred at
a single site, the Laureate Institute for Brain Research.
Participants were free to withdraw from participation
in the study at any time upon request.
The study investigator had the option to terminate
participation in the study if any clinical adverse event
(AE), laboratory abnormality, or other medical condition
or situation occurred such that continued participation
in the study would not be in the best interest of the participant, or if the participant met an exclusion criterion
(either newly developed or not previously recognized)
that precluded further study participation.
Procedures

The study medications were acquired through a local
compounding pharmacy in Tulsa, Oklahoma. The pharmacy dispensed and labelled the individual bottles of
study medication. A study psychiatrist provided the
medication to the subject at each in-house study visit.
The study medications were formulated into identical
compound capsules containing either (1) placebo + 10
mg escitalopram, (2) 5 mg MPH + 10 mg escitalopram,
(3) placebo + 20 mg of escitalopram, or (4) 5 mg MPH +
20 mg escitalopram. The study medications were packaged in standard bottles with a MEMS tracking cap. The
bottles were labeled with “Study Drug A”, “Study Drug

B”, “Study Drug C” or “Study Drug D”, the number of
capsules in the bottle and the administration date. At
the 4-week visit, participants had the option to increase
the escitalopram dose to 20 mg based on lack of clinical
improvement assessed by the study psychiatrist.
The following procedures (Supplemental Fig. 2) were
conducted during screening and enrollment (Week 0,
which lasted 3 h): (1) obtained informed consent of potential participant verified by signature on written informed consent form for screening and study consent
form; (2) recorded vital signs including temperature,
heart rate, electrocardiogram, systolic and diastolic blood
pressure; (3) recorded height and weight; (4) collected
urine for evaluation of pregnancy status (if applicable);
(5) obtained demographic information, medical history,
medication history, alcohol and tobacco use history; (6)
reviewed medical history and medications history to determine eligibility based on inclusion/exclusion criteria;
(7) collected self-report scales; (8) obtained blood safety
labs (CBC, CMP, TSH); (9) scheduled study visits for
participants who were eligible and available for the duration of the study; (10) provided participants with instructions for taking the study medication; and (11)
dispensed the study medication. During the follow-up
period the following procedures were conducted: (1)
weeks 1, 3 and 6 (phone call), the QIDS-SR and MAR
questionnaires were administered via phone, (2) weeks 2
and 4 (in-person visits), the study personnel verified inclusion/exclusion criteria, recorded vital signs including
temperature, heart rate, systolic and diastolic blood
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pressure, recorded current medications and interim
medical procedures, collected self-report scales including
QIDS-SR and medication adherence measures, conducted
the psychiatric visit (by a board certified psychiatrist) to
assess for medication side effects and treatment response,
and dispensed the relevant study medication.
Statistical rationale for pilot protocol

We proposed 20 participants for Stage 1 and 80 participants for Stage 2, both in 1:1 ratios for the two groups.
In Stage 1, the proposed sample size of 10 patients per
group was selected to provide an estimate of mean with
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
margin of error equivalent to t 10−1;0:975 1=10 ¼ 0:72
times the standard deviation for each group at 95% conpﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
fidence, or t 10þ10−2;0:975 1=10 þ 1=10 ¼ 0:94 times the
common standard deviation for between-group difference. We assumed a 20% dropout rate for both groups
at Week 8, the margin of error for the between-group
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
difference becomes t 8þ8−2;0:975 1=8 þ 1=8 ¼ 1:07 times
the common standard deviation. Stage 2 was designed
with an interim analysis. Assuming the primary endpoint
followed a Gaussian distribution, we controlled overall
Type I error rate at a 0.05 two-sided level using the
Hwang-Shih-DeCani spending function with γ parameter − 4 for the upper bound and − 2 for the binding
lower bound. We proposed a sample size of 40 patients
per group and anticipated a 20% dropout rate at Week
8, giving 32 patients per group or 64 in total. We set
n.fix in gsDesign() to 62 instead of 64 to obtain a final
sample size of 64. Because gsDesign() uses 1-sample zstatistic for continuous endpoint, the resulting effect size
θ = 0.3558 was converted to 2-sample Hedges’ G by a
factor of 2, i.e., g ≈ 0.71. For the maximum sample size
of 64, this design led to an expected sample size of 54.7
under this alternative hypothesis, or 42.8 under the null
hypothesis. Also, the variance of the primary endpoint
was unknown and was proposed to be estimated from
the sample, so z-tests were replaced with t-tests in
analyses and the bounds were revised accordingly. Based
on the quantile substitution method [66], the interim
boundaries 0.40 and 2.75 for z-distribution were
converted to 0.404 and 2.960 for a t-distribution with
32–2 = 30 degrees-of-freedom (df), and the critical zvalue 1.96 for the final analysis was converted to 1.999
for t-distribution with 64–2 = 62 df. We evaluated these
boundaries by 10,000-run simulation and confirmed that
(1) under null hypothesis, there was a 65.5% chance to
stop the trial for futility and a 0.3% chance to claim it
successful at interim analysis, and 0.024 one-sided Type
I error rate at final analysis; (2) under the alternative
hypothesis with an effect size of Hedges’ G 0.714, there
was only a 5.4% chance to stop the trial for futility and a
19.8% chance for success at the interim analysis, and
80.1% power at the final analysis.

Page 5 of 14

To ensure balance in-group size, we used block
randomization with block sizes of two. The
randomization sheet was provided by the primary statistician who was not involved in the clinical assessments
and given directly to the pharmacist. Investigators and
participants were kept blinded during the study window
until data collection and analysis were completed. All
study physicians, nurses and research assistants who
worked directly with participants were blinded to treatment allocation. Only the study statistician and one additional staff member who was assigned to work with the
compounding pharmacy were unblinded. Participants
were also asked to guess their treatment assignment and
indicate their degree of certainty and reasoning at each
in-person visit (Weeks 0, 2, 4 and 8).
Bayesian statistical analysis

We evaluated the treatment effect of each outcome by a
linear mixed-effects models with the following fixed
effects: treatment (MPH, Placebo), visit, and treatmentby-visit interaction. The data dependency was captured
by random participant intercepts. For the primary and
secondary outcomes, the Visit variable included 3 levels
(Week 2, 4, and 8) and the contrast of interest was the
MPH-vs.-placebo difference at Week 8; for the exploratory outcome QIDS score, the Visit variable included 7
levels (Week 0, 1, 2, 3, 4, 6, and 8) and the contrasts of
interest were the between-treatment differences in
changes at Week 8 from Week 0, i.e. the corresponding
interaction term. The. Parameters were estimated by the
rstan_lmer function from the R rstanarm package [67]
using the default and our informative priors. By default,
rstanarm package applies weakly informative priors [68],
where (1) the fixed-effects regression parameters follow
Gaussian prior with zero mean (except the mean of the
intercept is set to the sample mean) and standard deviation (SD) set to 2.5, (2) the SD of random error follows
an exponential distribution with the rate parameter set
to 1, (3) the variance of the random intercepts follows a
gamma prior with both the shape and the scale parameters set to 1. The default setup also applies an autoscale
function which automatically adjusts the SD in (1) and
the exponential rate parameter in (2) based on the data
scale. For the pilot study, we performed the Bayesian
analysis using these default priors, and conducted sensitivity analysis for the primary and secondary outcomes
with informative priors to pose our beliefs that MPS
would be superior to placebo. Specifically, we (a) replaced the zero mean in (1) with values such that the adherence rates were higher in the MPH group as
compared to the placebo group (96, 90, and 82% in
MPH vs. 90, 79, and 66% in placebo at Week 2, 4, and 8,
respectively), (b) set SD in (1) to 1, and (c) disabled the
autoscale function, and left all other settings as default.
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For all outcomes and priors, the Hamiltonian Monte
Carlo (HMC) was used for posterior sampling, and we
used the default 4 chains, where each chain consisted of
2000 iterations with the first 1000 discarded as warm-up.
Convergence was assessed by the Potential Scale Reduction Factor R-hat statistic. The analyses were conducted
using R version 4.0.2, the rstanarm package version 2.21.1,
and the tidybayes [69] package version 3.0.1.

Results
Subjects were recruited between January and March 2018.
For each group, we approached 23 participants and 23 were
assessed for eligibility, 20 were randomly assigned, 10 received intended treatment in each of 2 groups, and 20 were
assessed for the primary and secondary endpoint (Supplemental Fig. 1). The study was terminated in July 2018 at
the end of Stage 1 based on the results of the pilot data
showing the opposite direction to the hypothesis and low
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posterior probabilities that MPH was superior to placebo.
Stage 2 was not completed. There were no serious adverse
events. All results are reported based on the Intention to
Treat sample, which includes all randomized participants.
Participants who withdrew or were lost to follow-up were
considered non-adherent for the remainder of the study
schedule. Participants who withdrew from the study were
retained in the analyses. Three participants withdrew due
to medication side effects (2 MPH, 1 Placebo). One participant withdrew from the study due to missing study
appointments, including the final appointment (MPH).
Table 1 summarizes the socio-demographic and clinical characteristics of the participants. Briefly, there were
no differences across groups in any of the measures.
Primary outcome

Figure 1 and Table 2 summarize the main results for the
primary outcome measure, i.e. % adherence based on pill

Fig. 1 Summary of the main results for % adherence based on pill count (primary outcome). (a) Spaghetti plot of % pill count, (b) posterior
distributions of the LMM fixed-effect parameters: median (dots), 80% (think bars) and 95% (thick bars) credible intervals (CI), (c) the estimated
marginal means and 95% CI, (d) posterior density of between-treatment differences in adherence at Week 2, 4, and 8
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Table 2 Posterior estimates and contrasts for primary and secondary outcomes
Default priors

Informative priors

% pill counts (logit-scale)

Median

95% CI

Intercept

2.69

1.29

4.06

Median

95% CI

2.52

1.39

3.66

0.06

−1.85

1.90

0.39

−0.89

1.79

Visit Week 4

−0.13

− 0.68

0.42

− 0.25

− 0.8

0.24

MPH

Visit Week 8

−0.15

−0.74

0.42

−0.3

− 0.83

0.22

MPH-by-Week 4

−0.66

−1.47

0.15

−0.5

−1.22

0.25

MPH-by-Week 8

−1.07

−1.89

−0.23

−0.92

− 1.63

−0.17

Pr (MPH > placebo)
Week 2

0.526

0.713

Week 4

0.265

0.434

Week 8

0.144

% MEMS caps (logit-scale)

Median

0.250
95% CI

Median

95% CI

Intercept

2.75

1.41

4.2

2.51

1.3

3.54

MPH

−0.16

− 2.09

1.71

0.37

−0.98

1.72

Visit Week 4

−0.45

−1.04

0.09

−0.47

−1

0.02

Visit Week 8

−0.56

− 1.17

0.01

−0.62

− 1.13

− 0.09

MPH-by-Week 4

0.21

−0.6

1.01

0.18

−0.53

0.88

MPH-by-Week 8

−0.64

−1.45

0.19

−0.64

−1.36

0.09

Pr (MPH > placebo)
Week 2

0.442

0.698

Week 4

0.522

0.773

Week 8

0.209

0.356

count. The spaghetti plot (Fig. 1A) shows high adherence for both placebo (89%) and MPH (76%) condition,
respectively, average across visits. Due to the fact that
the distribution was highly skewed a logit transformation
was conducted. HMC chains converged for analyses with
the default weakly informative priors and our informative priors, with R-hat statistic ranging from 1.000 to
1.005 and from 1.00 to 1.010, respectively. Figure 1B
shows the posterior medians (dots), 80% (thin bars) and
95% (thick bars) credible intervals for the fixed-effect parameters. The estimated marginal means (EMS, Fig. 1C)
for treatment trajectories suggested lower adherence in
MPH than the placebo over time, and the betweentreatment contrasts (Fig. 1D) showed that there was less
than a 15.0% chance (default priors) that MPH would
show a higher adherence rate than placebo at Week 8
(Fig. 1D and Table 2). The same analysis using the informative priors suggested a higher but still low chance
(25.0%, Supplemental R markdown file).
Secondary outcome

The secondary endpoint for adherence was based on the
Medication Electronic Monitoring System (MEMS), i.e.
the % of doses taken on schedule within 25% of the expected time interval. HMC chains converged as R-hat

statistic ranging from 1.000 to 1.006 for both default and
the informative priors. Figure 2A and B show the spaghetti plots for each treatment group and the posterior
medians, 80 and 95% credible intervals (2B) for the
fixed-effect parameters, respectively. The EMS were
similar between treatments at Weeks 2 and 4, but
slightly lower in MPH at Week 8 (Fig. 2C). Similar to
the primary outcome measure, there was less than a
21.0% chance (the default priors) that MPH would show
a higher adherence rate than placebo (Fig. 2D and Table
2), and the contrasts from the informative priors
remained low (35.6%, Supplemental R markdown file).
Exploratory outcome and analyses

The exploratory endpoint was the remission rate according to the QIDS-SR scale for depression and the impact
of the BMQ scores for individual subjects on patterns of
adherence. HMC chains converged as R-hat statistic ranging from 1.000 to 1.005 for the default priors (we did
not apply informative priors for this exploratory outcome). Figure 3 shows the spaghetti plot (3A), posterior
medians, 80 and 95% credible intervals for the fixedeffect parameters (3B), and EMS for each treatment trajectory (3C). The spaghetti plot and the EMS suggested
QIDS scores reducing over time for both treatments. At
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Fig. 2 Summary of the main results for % adherence based on Medical Electronic Monitoring System (MEMS; secondary outcome). (a) Spaghetti plot
of % MEMS caps, (b) posterior distributions of the LMM fixed-effect parameters: median (dots), 80% (think bars) and 95% (thick bars) credible intervals
(CI), (c) the estimated marginal means and 95% CI, (d) posterior density of between-treatment differences in adherence at Week 2, 4, and 8

Week 8, the average QIDS changes from Week 0 was
1.2 points lower among patients receiving MPH as compared to those receiving placebo, however, the difference
could be 2.1 points higher to 4.5 points lower (Table 3).
Including additional covariates, i.e. age, sex, BMQ, did
not change the conclusions for either the primary or the
secondary outcome variable (results not shown).

Discussion
This exploratory randomized placebo-controlled clinical
trial evaluated the feasibility of combining a first-line
antidepressant plus MPH relative to a first-line antidepressant plus placebo in a capsule on rates of medication adherence in individuals with moderate to severe
depression. The Bayesian analysis that was applied to
primary, secondary and exploratory endpoints yielded
two main results. First, neither % Pill count nor MEMS
adherence showed that MPH was superior to placebo. In

fact, placebo showed slightly higher adherence rates on
the primary (7.82% better than MPH) and secondary
(7.07% better than MPH) outcomes, and there was a less
than 25% chance of MPH showing at least as good or
better than placebo adherence. Second, both groups
showed a significant effect of treatment on the QIDS-SR
with a median effect of an 8.6-point reduction. Third,
neither subjective measures of adherence attitudes using
the BMQ nor socio-demographic covariates had a significant influence on the primary or secondary outcome
variables. Taken together, these pilot data provide moderate evidence that MPH is not useful in increasing adherence to antidepressants in moderate to severely
depressed individuals.
The antidepressant treatment significantly improved
levels of depression in both groups and the effect size
was comparable to other trials using similar interventions [70]. Thus, the lack of effect of MPH could not
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Fig. 3 Summary of the main results for % adherence based on Quick Inventory of Depressive Symptomology (QIDS; exploratory outcome). (a)
Spaghetti plot of QIDS score with loess smooth curves (blue lines), (b) posterior distributions of the LMM fixed-effect parameters: median (dots),
80% (think bars) and 95% (thick bars) credible intervals (CI), (c) the estimated marginal means and 95% CI

have been due to a lack of efficacy of the primary treatment. On the other hand, the average adherence rate for
the primary outcome variable after 8 weeks of treatment
was 82% (with a credible interval of 67.2–97.3%). This
number is substantially higher than what has been obtained in other studies [6] and could be due to the intervention or the presence of the MEMS caps as well as the
relatively short follow up period. In combination, these
factors may have contributed to the difficulty in differentiating the effect of MPH versus placebo. The lack of efficacy of MPH in increasing adherence may be due to
several factors. First, a higher dose of MPH may induce
greater dopaminergic modulation and increase the possibility of transition from goal-directed to habitual behavior. Second, a longer follow up period may provide an
opportunity for MPH to counteract increasing nonadherence. Third, selecting depressed patient based on
greater anhedonia might provide a better clinical sample.

Nevertheless, improving adherence in general has been a
profoundly difficult challenge (e.g., see [71]).
To date, the available strategies for improving adherence include non-pharmacological approaches such as
reminders, support messages, social support engagement, care team contacts, data feedback, psychoeducation, adherence-based psychotherapy, remote care
delivery, secure medication storage, and contingency
management [72]. Some investigators have focused on
creating incentives for patients improves adherence. For
example, in one study participants received a small monetary reward for keeping an appointment and taking
their anti-retroviral medication. Those individuals receiving incentives were more likely to achieve 90% antiretroviral adherence compared with the control group
[73]. Similarly, while financial incentives increased
adherence to anti-hypertensives, none of the incentives
resulted in greater use of guideline-recommended
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Table 3 Posterior distributions of the fixed-effect parameters for
the exploratory outcome QIDS score
Parameter

Median

95% Credible Interval

Intercept

17.8

15.3

20.2

MPH

−1.62

−5.1

1.75

Week 1

−8.74

−11

−6.54

Week 2

−9.09

− 11.3

− 6.88

Week 3

−9.21

− 11.4

−7.04

Week 4

−7.32

−9.61

−5.18

Week 6

−9.44

−11.6

−7.25

Week 8

−8.77

−10.9

−6.52

MPH:Week 1

1.78

−1.33

5.04

MPH:Week 2

2.77

−0.34

5.87

MPH:Week 3

0.79

−2.33

3.9

MPH:Week 4

0.79

−2.45

3.95

MPH:Week 6

0.26

−2.93

3.35

MPH:Week 8

−1.18

−4.46

2.06

medications [74], which is consistent with minimal effects during a large post-myocardial infarction study
[75]. Although there is no evidence that incentives reduce motivation to take antipsychotic medications [76],
there is also minimal increase in adherence for antipsychotic medication without significant symptomatic
improvement when patients are incentivized [77, 78].
While others found some increase in adherence during
the incentive phase for injectable antipsychotics, this effect did not last past the incentivization period [79],
which was also observed in patients with bipolar disorder [80]. In a shared incentive study, shared financial
incentives for physicians and patients, but not incentives
to physicians or patients alone resulted in increased statin adherence [81]. This is consistent with a review
examining 22 randomized clinical trials focused on promoting adherence to antidepressants by incentivizing
providers, which did not have a significant effect [82].
There is also little evidence that these interventions
reduce overall mental health care costs [76]. Taken
together, non-adherence to medication remains a very
difficult problem that has profound effects on individual
long-term outcomes.
Another finding from the current study was that participants attitudes, as measured by the BMQ, did not
affect adherence rates. This questionnaire probes the
‘necessity-concerns framework’ [63], which provides a
heuristic approach to understand patients’ adherence behavior. This framework proposes that the decision to
take a medication is mediated by two opposing beliefs,
i.e. beliefs about the necessity of taking the medication
for a particular condition versus concerns about negative
effects associated with taking medications. In a meta-

analysis across different medical conditions and treatments, this framework significantly and differentially
predicted rates of adherence [83]. For example, for each
standard deviation increase in necessity beliefs, the odds
of adherence increases by a factor of 1.7 and for each
standard deviation increase in concerns, the odds of adherence decreases by a factor of 2 [84]. In comparison,
both BMQ overuse and general harm subscores had negligible effects on both primary and secondary outcomes
in this study. Moreover, depression [85] has been shown
to moderate this relationship [86] with influences particularly on the concerns aspect of the framework [87].
The antidepressant-specific “necessity-minus-concerns”
composite has been proposed as a predictor for adherence [88] and there is evidence that attitudes and beliefs
are at least as important as side effects in predicting adherence [89]. For example, those individuals who have
higher levels of concerns about antidepressant medications are less likely to be adherent [90] whereas those
who report high initial expectations show greater adherence, even to placebo interventions [91]. Non-initiators
have lower belief scores for impact of illness, intention
to take medication, and attitude towards medication
[92]. Others have found that while intentional nonadherers had higher concerns scores, unintentional nonadherers did not, which emphasizes the heterogeneity of
non-adherence [93]. Moreover, those individuals who reported high necessity and high concern beliefs, i.e. were
ambivalent, also showed lower levels of adherence [94].
Not surprisingly, greater non-adherence is also related
to higher depression scores at follow up [95]. Interestingly, beliefs about causes of depression seem to matter
little in antidepressant adherence [96]. It is likely an adherence study with more participants than were examined in this pilot study would be necessary to examine
the contributions of these attitudes on adherence
interventions.
The Bayesian framework provides a powerful and intuitive approach when applied to a pilot study such as
this [97]. First, the Bayes factors quantitatively assessed
the degree to which different models best described the
observed data. Bayes factors are likelihood ratios, i.e.
they describe how much more likely the observations
are due to a particular model, relative to the random
variation that is due to the individual differences of the
participating subjects. The magnitude of the Bayes factors provides the strength of the evidence. The magnitude of the Bayes factor for the primary and secondary
endpoints in this study was modest, i.e. providing “moderate” evidence [98]. Moreover, the posterior distributions give probability estimates of the outcome variable
based on the best model. This enables one to not just
provide a point measure, e.g. the mean or median, but
also a range given by a credible interval. The results of
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this study showed that the credible intervals of the estimates are large and included zero, but that the probability of a desired effect by MPH was less than one in four
for both primary and secondary outcomes. An important
advantage is that these estimates can be used to determine whether it is useful to continue a study or whether
it is preferable to stop the study. The outcomes observed
in this trial, which showed a slight advantage of placebo,
led us to the decision to stop the trial. This two-stage
strategy could be extended to other trials and may provide a reasonable heuristic to conduct pilot studies with
novel drugs to determine whether to advance to fullscale efficacy trials.
This study has several limitations. First, given the
small number of participants and the single-sided nature
of the study, one needs to be careful about
generalizability and about the precision of the observed
effects. In addition, due to large variation of estimates of
measures of central tendency in small samples, one
should use caution when using pilot studies to guide
power calculations for study continuation [99]. Second,
there is no gold standard for adherence. Although the
outcome measures selected here have been proposed as
reasonable adherence measures, it is well-known that
different assessments can yield varied outcomes. Considering this fact, the similarity of the primary and secondary outcome effects was remarkable. Third, this pilot
trial did not include a placebo treatment group. Thus, it
is difficult to determine whether the effect on the exploratory outcome (QIDS-SR) was due to escitalopram
or an effect of time. Therefore, we cannot speak to the
efficacy of the antidepressant treatment itself.
In conclusion, the goal of this pilot study was to determine whether low-dose MPH would facilitate building
the habit to take antidepressant medication and showed
that it failed. Future interventions may focus on other
approaches to facilitate habit formation as it relates to
medication adherence.
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